J&J Risperdal for autism (clarification)
Executive Summary
While Risperdal (risperidone) has been studied for aggression and other behavioral traits of autism, the official indication being sought for the antipsychotic drug is for "treatment of autism in children and adolescents," J&J says. The company filed the NDA in December (1"The Pink Sheet" April 19, p. 12)...
You may also be interested in...
J&J Antipsychotic Paliperidone ER Moves Into Phase III
Johnson & Johnson has moved a potential successor compound to the antipsychotic Risperdal into Phase III clinical studies
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.